AnaptysBio <Momenta< J&J $强生(JNJ)$ $摩蒙塔制药(MNTA)$ $AnaptysBio(ANAB)$查看全文
美股滚雪球2022-09-13 14:51
$AnaptysBio(ANAB)$ 宣布将与葛兰素史克(GSK)合作的口腔癌治疗药物Zejula的全球净销售额的专利权益,以4500万美元的价格出售给加拿大DRI医疗信托公司。
根据合同条款,ANAB已经获得了3500万美元的销售预付款。如果FDA在2025年12月31日或之前批准Zejula用于子宫内膜癌,该公司将有权从DRI获得另...查看全文
SeekingBiotech2022-09-12 21:34
AnaptysBio sells royalties from GSK-partnered Zejula for $45M.
PARP持有的权益转让为了现金流。$AnaptysBio(ANAB)$查看全文
SeekingBiotech2022-09-10 11:55
JXSL2200093 Imsidolimab注射液 AnaptysBio Inc. 用于治疗泛发性脓疱型银屑病(GPP) 1
IL-36查看全文
医药笔记2022-04-26 13:41
2022年4月26日,华海药业子公司华博生物HB0034注射液的临床试验申请获得NMPA受理。
HB0034为IL-36R抗体,也是国内首款申报临床的IL-36R抗体。IL-36Rα 、β、γ结合IL-36R,后者随之与IL-1RAcP形成异源二聚体,进而激活胞内下游信号通路。
IL-36R参与多种自身免疫病的发病机制。
IL-36...查看全文
医药笔记2022-03-15 14:18
▎Armstrong
2022年3月14日,AnaptysBio宣布IL-36R抗体Imsidolimab治疗痤疮的二期临床ACORN没有达到疗效的主要终点和次要终点。
受此消息影响,AnaptysBio股价在盘后下跌近10%。
Imsidolimab为AnaptysBio自主管线中首个产品,在探索脓疱型银屑病、痤疮、化脓性汗腺炎等三中适应症。
chuminhua2022-03-15 10:11
5月14日,AnaptysBio $AnaptysBio(ANAB)$ 的股价在盘后交易中暴跌近 13%,此前该公司表示将结束开发 imsidolimab 作为痤疮治疗药物的努力,因为它在 II 期研究的主要或次要终点上的表现并不优于安慰剂。 “尽管 ACORN 试验的结果令人失望,”首席执行官 Hamza Suria 表示,“但我们期待 imsidolima...查看全文
$AnaptysBio, Inc.(ANAB)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2017-10-02 AccNo: 0000902664-17-003874 Size: 111 KB 网页链接
$AnaptysBio, Inc.(ANAB)$ 8-K - Current report Filed: 2017-08-24 AccNo: 0001193125-17-266085 Size: 33 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9.01: Financ...
$AnaptysBio, Inc.(ANAB)$ 8-K - Current report Filed: 2017-08-24 AccNo: 0001193125-17-266085 Size: 33 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9.01: Financ...
$AnaptysBio, Inc.(ANAB)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-08-10 AccNo: 0001370053-17-000012 Size: 5 MB 网页链接
$AnaptysBio, Inc.(ANAB)$ 8-K - Current report Filed: 2017-08-10 AccNo: 0001370053-17-000010 Size: 173 KBItem 2.02: Results of Operations and Financial Condition 网页链接
$AnaptysBio, Inc.(ANAB)$ 8-K - Current report: n Filed: 2017-07-27 AccNo: 0001193125-17-238462 Size: 15 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$AnaptysBio, Inc.(ANAB)$ 8-K - Current report: n Filed: 2017-07-27 AccNo: 0001193125-17-238462 Size: 15 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$AnaptysBio, Inc.(ANAB)$ 8-K - Current report: n Filed: 2017-07-27 AccNo: 0001193125-17-238462 Size: 15 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$AnaptysBio, Inc. Common Stock(ANAB)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-05-12 AccNo: 0001370053-17-000005 Size: 4 MB 网页链接
$AnaptysBio, Inc. Common Stock(ANAB)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-05-12 AccNo: 0001370053-17-000005 Size: 4 MB 网页链接